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Abstract
Introduction: Hyperlactatemia represents one prominent component of the metabolic response to sepsis. In
critically ill patients, hyperlactatemia is related to the severity of the underlying condition. Both an increased
production and a decreased utilization and clearance might be involved in this process, but their relative
contribution remains unknown. The present study aimed at assessing systemic and muscle lactate production and
systemic lactate clearance in healthy human volunteers, using intravenous endotoxin (LPS) challenge.
Methods: Fourteen healthy male volunteers were enrolled in 2 consecutive studies (n = 6 in trial 1 and n = 8 in
trial 2). Each subject took part in one of two investigation days (LPS-day with endotoxin injection and placebo-day
with saline injection) separated by one week at least and in a random order. In trial 1, their muscle lactate
metabolism was monitored using microdialysis. In trial 2, their systemic lactate metabolism was monitored by
means of a constant infusion of exogenous lactate. Energy metabolism was monitored by indirect calorimetry and
glucose kinetics was measured with 6,6-H2 glucose.
Results: In both trials, LPS increased energy expenditure (p = 0.011), lipid oxidation (p<0.0001), and plasma lactate
concentration (p = 0.016). In trial 1, lactate concentration in the muscle microdialysate was higher than in blood,
indicating lactate production by muscles. This was, however, similar with and without LPS. In trial 2, calculated
systemic lactate production increased after LPS (p = 0.031), while lactate clearance remained unchanged.
Conclusions: LPS administration increases lactatemia by increasing lactate production rather than by decreasing
lactate clearance. Muscle is, however, unlikely to be a major contributor to this increase in lactate production.
Trial registration: ClinicalTrials.gov NCT01647997
Introduction
Sepsis and inflammation elicit a whole set of neuroen-
docrine, metabolic, and systemic responses that belong
to the organism’s defense mechanisms [1,2]. However,
when excessive, these responses may also exert deleter-
ious effects [3]. Hyperlactatemia represents one promi-
nent component of the metabolic stress response but
shows marked inter-individual variations [4-6]. In criti-
cally ill patients, hyperlactatemia has been shown to be
related to both the severity of the underlying condition
and in-hospital mortality [7].
The mechanisms underlying the development of
hyperlactatemia in sepsis remain poorly understood:
increased production or decreased clearance or a combi-
nation of both are possible [8]. A rise in plasma lactate
concentrations may result from a decreased lactate
clearance secondary to low tissue oxygen delivery [9,10]
or from an increase in lactate production secondary to
anaerobic metabolism in under-perfused tissues or to
stimulation of aerobic glycolysis in response to inflam-
matory mediators [11,12]. The relative importance of
these two processes, as well as the major tissues where
lactate metabolism is altered by sepsis, remains incom-
pletely understood.
The impact of inflammation on the different metabolic
pathways can be investigated by using a reproducible
model of acute inflammation, consisting of endotoxin
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administration (lipopolysaccharide = LPS) [13], which
closely mimics some important aspects of sepsis and has
the advantage of being short-lived. LPS elicits the release
of inflammatory mediators such as tumor necrosis fac-
tor-alpha (TNF-a) and interleukins (ILs) [14-17] and
reproduces most of the neuroendocrine and metabolic
alterations.
The present study aimed at investigating the relation-
ship between inflammation and lactate metabolism and
comparing local muscle responses and systemic metabo-
lism. The objectives were to investigate the effect of
endotoxin on the muscle lactate production in a first set
of studies (trial 1) and on whole-body endogenous lactate
production and lactate clearance in a second set of stu-
dies (trial 2). Since lactate is a major gluconeogenic pre-
cursor, an additional aim of this study was to evaluate
the effects of an increased lactate supply on glucose pro-
duction and glycemic control during endotoxin-induced
sepsis-like conditions.
Materials and methods
Subjects and protocol
The study was conducted with institutional ethics com-
mittee approval (Commission cantonale (VD) d’éthique
de la recherche sur l’être humain) and individual signed
informed consent. Fourteen healthy male volunteers were
enrolled, and each subject took part in one of two conse-
cutive parts of this study. The subjects were studied in a
random order and on two occasions separated by at least
one week: once with endotoxin administration (LPS day)
and once with placebo (placebo day). Inclusion criteria
were age of between 18 and 30 years and body mass
index (BMI) of between 19.5 and 25. Exclusion criteria
were family history of metabolic or endocrine disease,
smoking, alcohol consumption, and current medication.
The study design is summarized in Figure 1.
The subjects came to the metabolic laboratory at 7 a.m.
after an overnight fast. Upon arrival, they were requested
to void, and the urine was discarded. Thereafter, they
remained supine quietly in a bed for the next 10 hours.
An antecubital vein was cannulated for labeled tracer
infusion. A dorsal hand vein of the opposite arm was can-
nulated to collected blood samples. This hand was placed
in a thermostabilized box, which was heated at 50°C to
achieve partial arterialization of venous blood.
After stabilization and tracer equilibration, endotoxin
(LPS day: 2 ng/kg; US Pharmacopeial Convention, Rock-
ville, MD, USA) or placebo (placebo day: NaCl 0.9%) was
administrated as an intravenous bolus (T0).
Blood samples were collected at regular intervals up to
390 minutes later (T390) to determine glucose, triglycer-
ides, free fatty acids (FFAs), insulin, glucagon, lactate,
cortisol, adrenocorticotropine (ACTH), norepinephrine,
epinephrine, TNF-a, IL-6, and C-reactive protein (CRP)
concentrations and to determine plasma 6,6 2H2 glucose
isotopic enrichment. Blood samples were collected into
heparinized tubes and centrifuged to separate plasma.
Plasma was stored at -20°C (-80°C for catecholamines)
until analysis.
Oxygen consumption and CO2 production measured
by indirect calorimetry (by means of open-circuit indirect
calorimetry as described previously [18]) were used to
determine the energy expenditure [19]. Urine was
sampled from spontaneous voiding throughout the study
to assess the urinary urea nitrogen excretion. Heart rate,
rectal temperature (Hellige; Servomed, Cairo, Egypt),
arterial pressure, cardiac output by bioimpedance
(NCCOM3 cardiodynamic monitor; BoMed, Irvine, CA,
USA), and oxygen saturation (Biox 3740 Pulse oximeter;
Ohmeda, now part of GE Healthcare, Little Chalfont,
Buckinghamshire, UK) were monitored throughout the
experiments.
Glucose turnover (trials 1 and 2)
After blood sampling for determination of basal glucose
isotope enrichment and basal lactate, a primed continu-
ous infusion of 6,6 2H2 glucose (Cambridge Isotope
Laboratory, Cambridge, MA, USA; prime 3 mg/kg per
minute, continuous 30 μg/kg per minute) was infused
from T180 (180 minutes before intravenous endotoxin
or placebo) throughout the study.
Microdialysis (trial 1)
One microdialysis probe (CMA; Carnegie Medicine,
Stockholm, Sweden) was inserted into the muscle vastus
lateralis of one thigh and was infused with a Ringer solu-
tion containing 1 mmol/L 13C3 lactate (Cambridge Iso-
tope Laboratory) at a rate of 0.3 μL per minute
throughout the experiment. The cutoff of the microdialy-
sis membrane was 30 kDa. Microdialysates were collected
every hour to evaluate interstitial muscle lactate concen-
trations. The dialysate was collected at 60-minute inter-
vals for measurement of dialysate lactate and 13C lactate
concentrations.
Figure 1 Study design. LPS, lipopolysaccharide.
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Lactate clearance (trial 2)
Changes in lactate clearance and production elicited by
endotoxin were evaluated by means of a continuous exo-
genous lactate infusion, as previously described [20].
Lactate (10 μmol/kg per minute) was infused from T90
until T270. Systemic lactate kinetics (lactate clearance
and endogenous production) were assessed by means of
a modified method of Connor and colleagues [21].
Analytical procedures
Substrate analysis
Plasma glucose concentrations were measured enzymati-
cally by using a YSI 2300 Stat Plus (YSI Incorporated,
Yellow Springs, OH, USA), and plasma FFA concentra-
tions were measured with a colorimetric method and a
kit from Wako Chemicals GmbH (Neuss, Germany).
Triglyceride levels were analyzed enzymatically by using
the PAP 150 test (bioMérieux, Marcy l’Etoile, France).
The urine nitrogen excretion rate was determined by
means of the micro-Kjeldahl method. Concentrations of
ACTH were determined with a chemiluminescence assay
kit (Nichols Institute Diagnostics, San Juan Capistrano,
CA, USA). Concentrations of insulin (kit from Adaltis,
Casalecchio di Reno, Italy), cortisol (kit from Diagnostic
Products Corporation, Los Angeles, CA, USA), and glu-
cagon (kit from Linco Research, St. Charles, MO, USA)
were determined by radioimmunoassay. Plasma concen-
trations of bioactive IL-6 and TNF-a were determined by
using radioimmunoassay. CRP was analyzed by turbidi-
metry on a Hitachi 917 (Roche, Basel, Switzerland) by
using reactants produced by Dako Schweiz AG (Baar,
Switzerland). Plasma catecholamines were determined by
high-performance liquid chromatography with electro-
chemical detection [22]. Plasma 6,6 2H2 glucose isotopic
enrichments were determined on deproteinized samples
partially purified over sequential cation-anion exchange
resins (AG 1-X8 and AG 50W-X8; Bio-Rad Laboratories,
Richmond, CA, USA). For glucose measurements, pen-
taacetyl glucose was analyzed with gas chromatography-
mass spectrometry (Hewlett-Packard, Palo Alto, CA,
USA) [23]. Dialysate lactate concentration was measured
by using a CMA microdialysis analyzer 600. The 13C lac-
tate enrichment was measurement by gas chromatogra-
phy-mass spectrometer, as previously described [24].
Calculations
Glucose rates of appearance and utilization (trials 1 and
2) were calculated from 6,6 2H2 glucose by using Steele’s
equations for non-steady state [25]. Substrate oxidation
and energy expenditure were calculated from respiratory
gas exchanges and urinary urea nitrogen excretion rates
by using the equations of Livesey and colleagues [26]
corrected for urinary bicarbonate excretion rate [27].
For microdialysis measurements (trial 1), tissue sub-
strate production is reflected by a positive gradient of
concentration between the dialysate and the systemic
circulation. This gradient was calculated as the differ-
ence of dialysate concentrations and systemic plasma
concentrations, and a near-complete substrate recovery
at the low flow rate (0.3 μL per minute) used in these
experiments was assumed. Interstitial lactate concentra-
tions were calculated by dividing dialysate lactate con-
centration by the recovery of infused 13C lactate, as
described [24,28].
Lactate clearance (trial 2) was calculated as the quoti-
ent of exogenous lactate infusion rate and the plasma
lactate difference (Δ lactate) induced by lactate infusion.
Delta lactate was calculated from basal concentration
(mean from T-150 to T-120) and plateau concentrations
(mean from T-30 to T0) due to the start of lactate infu-
sion as well as from plateau (mean from T240 to T270)
and the fall to final lactate levels (mean from T360 to
T390) due to the stop of lactate infusion. This proce-
dure assumes that lactate concentrations do not vary
significantly 5 hours after LPS administration. This has
been documented in an earlier study performed in our
lab [29].
Statistical analysis
Data were analyzed by using one-way or two-way analy-
sis of variance (ANOVA) as appropriate. To determine
whether lactate perfusion has an influence on the
inflammatory response, two-way ANOVA was used to
compare placebo groups of each trial. Post hoc analysis
(Tukey test) was used in the presence of statistically sig-
nificant changes. A P value of less than 0.05 was consid-
ered significant. The statistical package was JMP 8.0
(SAS Institute, Inc., Cary, NC, USA).
Results
Characteristics of subjects were similar in the two trials
(trial 1: n = 6; trial 2: n = 8): mean ages of 27.1 ± 2.4
and 26.7 ± 3.3 years, mean body weights of 74.8 ± 3.4
kg and 75.0 ± 6.9 kg, and mean BMIs of 24.0 ± 2.2 kg/
m2 and 23.9 ± 1.8 kg/m2, respectively.
General and hemodynamic effects of lipopolysaccharide
All subjects complained of headache, myalgia, and nau-
sea. After LPS, significant increases in body temperature
(mean peak at T240 of +1.7°C; P <0.0001) (Figure 2)
and heart rate (mean peak of +38 beats per minute)
(Figure 2) were observed, whereas mean blood pressure
did not decrease significantly. Transcutaneous oxygen
saturation remained normal in all subjects.
Acute neuroendocrine and cytokine responses
After endotoxin administration, plasma cortisol (Figure
3) increased significantly (P <0.0001), peaking at T240.
TNF-a also increased significantly (P <0.0001), peaking
at T90, and was followed by a peak of IL-6 secretion
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between T120 and T150. Compared with trial 1, the
increases in plasma IL-6 and cortisol were more sus-
tained in trial 2 after exogenous lactate infusion. The
stress hormones epinephrine and norepinephrine only
were determined in trial 2 to have peaked at 120 min-
utes after LPS for norepinephrine and at 240 minutes
after LPS for epinephrine.
Metabolic effects
Resting energy expenditure increased significantly in
response to endotoxin (P = 0.011). Glycemia did not dif-
fer significantly at baseline. In both protocols, plasma
glucose concentrations showed a biphasic response to
endotoxin; an initial maximal decline occurred 2 hours
after endotoxin administration, and a moderate rebound
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Figure 2 Evolution of temperature and energy expenditure during the trial in four sessions.
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increase occurred between 3 and 6 hours after endo-
toxin (Figure 4). At T360, glycemia was still significantly
higher in the endotoxin subjects of trial 2 in comparison
with those of trial 1 (106 versus 91 mg/dL; P <0.0001).
These changes were related to trends toward a reduced
endogenous glucose production concomitant with a
modest increase in metabolic glucose clearance early
after endotoxin over the first hour after endotoxin, fol-
lowed by an increase in glucose production, which was
sustained throughout the remaining observation time.
Endotoxin administration also elicited a 70% increase in
plasma glucagon (from 64.6 to 107.4 ng/L at T120 in
trial 1 and from 62.5 to 108.1 ng/L at T240 in trial 2)
and enhanced the progressive increase in plasma FFA
observed in placebo studies, as previously reported [30].
Plasma insulin concentrations were not affected by
endotoxin. In trial 1, endotoxin significantly increased
energy expenditure, and this increase was sustained over
the 6-hour period of observation. A stimulation of lipid
oxidation accounted for this increase in energy expendi-
ture whereas glucose oxidation was unchanged.
Lactate metabolism
In trial 1, LPS substantially increased the plasma lactate
concentrations (Figure 5). Lactate concentrations peaked
at T90 and declined progressively thereafter but
remained higher than in the control experiment until
the end of the observation period. Muscle interstitial
lactate concentrations were systematically higher than
plasma lactate concentrations, and their increase paral-
leled that of plasma lactate. The difference between
interstitial lactate concentration and plasma lactate con-
centration (that is, lactate gradient from muscle towards
plasma) (Figure 5) remained constant.
In trial 2, exogenous lactate infusion achieved a steady
plasma lactate concentration during the 30-minute per-
iod preceding LPS administration and during the third
hour following endotoxin administration (Figure 6). At
the end of the exogenous infusion, plasma lactate
declined rapidly in both LPS and placebo arms but sta-
bilized at slightly higher values after endotoxin. Lactate
production and clearance calculated during these peri-
ods are shown in Table 1. Lactate production was signif-
icantly increased after endotoxin, whereas lactate
clearance was not altered.
Discussion
The present study corroborates earlier reports showing
that an acute LPS challenge is a suitable model for the
investigation of acute neuroendocrine and metabolic
alterations elicited by bacterial infection and early sepsis
[14-17,30]. Several key features of early sepsis - that is,
acute transient increases in body temperature and heart
rate, increases in plasma cytokines and stress hormone
concentrations, a hypermetabolic state, and alterations
of glucose homeostasis - were reproduced.
Administration of endotoxin increased total energy
expenditure by about 35%. This increase was totally
accounted for by a stimulation of lipid oxidation,
whereas carbohydrate oxidation was not altered. This
conclusion rests on the observation that, owing to fast-
ing, net carbohydrate oxidation decreased continuously
throughout the experiment but was similar in endotoxin
and control experiments. Stimulation of lipolysis, pre-
sumably in adipose tissue [31], was documented by an
accentuated increase in plasma FFA in comparison with
control subjects and was most likely operative in fueling
lipid oxidation.
Although endotoxin did not increase net glucose oxi-
dation, it exerted significant effects on glucose homeos-
tasis. In control subjects, a progressive decline in
glucose production and glycemia was observed as a
result of fasting. In contrast, administration of endotoxin
tended to accentuate this drop in glucose production
during the first hour but then consistently and continu-
ously increased glucose production. This effect of endo-
toxin on glucose production is consistent with previous
reports in humans and animals in response to adminis-
tration of endotoxin and TNF-a and accounts for endo-
toxin-induced hyperglycemia since the metabolic
clearance of glucose was essentially unaffected. Several
studies have reported that bacterial endotoxin or admin-
istration of inflammatory cytokines induces a transient
decrease in plasma glucose and an increase in glucose
production and glucose utilization in fasted organisms
[17]. Our present observations corroborate and extend
these observations by showing that the increase in glu-
cose utilization corresponds essentially to a stimulation
of non-oxidative glucose disposal.
As a result of endotoxin administration, plasma lactate
concentration increased consistently, peaked after 90
minutes, and progressively decreased thereafter. Plasma
lactate, however, remained elevated throughout the 390-
minutes observation period. Lactate concentrations in
muscle interstitial fluid (trial 1) were significantly higher
than plasma concentration throughout the experiment.
This, however, was observed both in control experi-
ments and after endotoxin and was not enhanced by
endotoxin. This constant positive muscle-to-plasma gra-
dient of lactate suggests that muscle lactate production
was not increased by LPS. However, two limitations to
the microdialysis technique need to be addressed. First,
since muscle simultaneously produces and uses lactate,
we cannot discard the hypothesis that both processes
were increased to the same extent and hence that mus-
cle lactate turnover was increased. However, if this was
the case, it would not increase the net lactate efflux
from muscle and therefore it would not participate in
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whole-body lactate production as measured in the pre-
sent experiments. Second, an increased muscle lactate
production may have resulted in a constant muscle-to-
plasma lactate gradient if muscle blood flow had
increased in the same proportion. Although this was not
measured in our experiments, several reports indicate
that muscle blood flow is not increased and may even
be decreased after LPS in humans [32] and rats [33] and
in patients with sepsis [34]. If muscle blood flow is
assumed not to have increased in our experiments, the
absence of an increased interstitial muscle-arterial gradi-
ent after LPS indicates that skeletal muscle produces
lactate in fasting conditions but that this was not stimu-
lated by endotoxin.
In trial 2, lactate kinetic was assessed by monitoring
plasma lactate concentrations during continuous infusion
of exogenous lactate. Continuous infusion of lactate is a
variant of the bolus lactate administration approach
[35-37], which we have described in detail elsewhere [20],
and rests on the assumption that endogenous lactate pro-
duction is not significantly affected by exogenous lactate,
an assumption that is supported by a previous isotopic
study [38]. Calculations of lactate clearance and produc-
tion with such an approach require that plasma lactate
concentration not vary markedly over time, and hence
such calculations were possible only in basal conditions
and during the fourth hour after endotoxin administra-
tion. For the latter, however, lactate concentrations
tended to decrease over time in the placebo experiment
of trial 2, implying that some underestimation of lactate
production and overestimation of lactate clearance
cannot be excluded. The data obtained from exogenous
lactate infusion provide calculation of basal lactate pro-
duction that were similar in both control and endotoxin
experiments and were comparable to values reported in
the literature with bolus lactate administration [35,36].
During the fourth hour after endotoxin administration,
lactate clearance was unchanged, indicating that
increased lactate production was responsible for the
development of hyperlactatemia.
It may have been hypothesized that the increase in glu-
cose production observed after administration of endo-
toxin was secondary to an increased gluconeogenesis
from lactate. This hypothesis is consistent with the fact
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that the increase in lactate production (that is, about 4
μmol/kg per minute) closely matched the increase in glu-
cose production (that is, about 0.5 mg/kg/min, corre-
sponding to about 3 μmol/kg per minute). Our results
obtained during lactate infusion, however, strongly sug-
gest that the increase in glucose production was not
directly dependent on lactate supply, since exogenous
lactate did not further increase glucose production.
Similar reports, in which lactate infusion stimulates glu-
coneogenesis but fails to enhance overall glucose produc-
tion, have been reported in both healthy subjects [38]
and critically ill patients [39]. This apparently surprising
observation can be explained by an autoregulation of glu-
cose production. According to this concept, glycemia per
se regulates hepatic glucose output whereas acute altera-
tions of gluconeogenesis lead merely to mirror changes
in glycogenolysis [40]. Our present observation, by show-
ing that endogenous glucose production is increased
even though plasma glucose is higher (a factor that
would normally inhibit hepatic glucose output), clearly
indicates alterations of hepatic glucose metabolism. How-
ever, failure of exogenous lactate to further increase
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glucose production and glycemia indicates that hepatic
glucose production is still efficiently autoregulated after
endotoxin. This indicates (a) that increased gluconeo-
genic precursor availability is not the major factor
responsible for an increase in glucose output and (b) that
endotoxin administration increases fasting glycemia by
resetting autoregulation of hepatic glucose production
toward a higher glycemic level.
It must be emphasized, though, that our subjects had
been fasted overnight before the test, and this affects
glucose metabolism [41] but also the response to LPS,
as in the trial by Fong and colleagues [42]. Depending
on whether the clinician uses early enteral or parenteral
nutrition, the flux of lactate may be affected differently
in critically ill patients, and therefore our results in
healthy subjects may not apply directly.
Conclusions
These observations indicate that, in healthy humans,
LPS administration leads to consistent increases in
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plasma lactate concentrations secondary to a stimulation
of lactate production. However, the microdialysis data
suggest that - provided that there was no increase in
muscle blood flow - skeletal muscle was not a major
contributor to LPS-induced lactate production. Further
studies will be required to further evaluate which tissues
are involved in LPS-induced lactate production, but
immune cells and the reticulo-endothelial systems are
obvious candidates as they are prime targets of cyto-
kines secreted in response to LPS. Endotoxin adminis-
tration increased fasting glucose concentration and
endogenous glucose production, but this effect does not
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appear to be directly related to a stimulation of glucose
production by enhanced lactate availability.
Key messages
• Endotoxin administration leads to increased
plasma lactate concentrations.
• Resting energy expenditure increased significantly
in response to endotoxin.
• This increase is caused by a stimulation of glucose
and lactate production.
• This increased lactate production does not occur
in the muscle.
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